Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy
Retrieved on:
Wednesday, April 7, 2021
The claims of EP3317301 are directed to embodiments of LAG525, a humanised form of Immuteps IMP701 antibody which is out-licensed to Novartis AG.
Key Points:
- The claims of EP3317301 are directed to embodiments of LAG525, a humanised form of Immuteps IMP701 antibody which is out-licensed to Novartis AG.
- In particular, the claims of the patent are directed to compositions comprising LAG525 and spartalizumab, an anti-PD-1 antibody molecule, and related methods of use of the combination in the treatment of cancer.
- The patent is co-owned by Novartis AG and Immutep S.A.S.
- IMP701 is a therapeutic antibody originally developed by Immutep S.A. (now Immutep S.A.S.)